Our findings are strongly supported by clinical data and previous reports (Crowder et al, 2004; Nagata et al, 2004; Pandolfi, 2004) that PTEN-deficient tumours did not respond to trastuzumab. The gene discussed is PTEN; the disease is neoplasm.